Adriamycin binding assay: a valuable chemosensitivity test in human osteosarcoma

Nicola Baldini, Katia Scotlandi, Massimo Serra, Katsuyuki Kusuzaki, Toshiharu Shikita, Maria C. Manara, Daniela Maurici, Mario Campanacci

Research output: Contribution to journalArticlepeer-review


The reliability of a simple method evaluating the pattern of subcellular binding of Adriamycin (Adriamycin binding assay, ABA) as an index of sensitivity was demonstrated in different primary cultures and in sensitive and resistant cell lines of human osteosarcoma. After exposure to Adriamycin (10 μg/ml for 30 min at 37°C), living sensitive cells showed selective intranuclear uptake of the drug, whereas in resistant cells no distinct subcellular distribution was observed. The binding pattern of Adriamycin in sensitive and in highly resistant cells was inversely related to the expression of P-glycoprotein. However, low levels of resistance in vitro, not detectable by increased levels of expression of P-glycoprotein, were revealed by ABA. The use of ABA in combination with the estimate of P-glycoprotein expression is recommended in clinical practice as an accurate means for predicting the sensitivity of osteosarcoma to Adriamycin.

Original languageEnglish
Pages (from-to)121-126
Number of pages6
JournalJournal of Cancer Research and Clinical Oncology
Issue number2
Publication statusPublished - Feb 1992


  • Adriamycin
  • Chemosensitivity
  • Osteosarcoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Adriamycin binding assay: a valuable chemosensitivity test in human osteosarcoma'. Together they form a unique fingerprint.

Cite this